Skip to main content
SpringerLink
Log in

Disfunzioni tiroidee in pazienti con tumori solidi trattati con farmaci inibitori delle tirosino-chinasi

  • Rassegna
  • Published:
L'Endocrinologo Aims and scope

Sommario

Con l’utilizzo dei nuovi farmaci a bersaglio molecolare chiamati inibitori delle tirosino-chinasi (TKI), la sopravvivenza dei pazienti metastatici è nettamente migliorata. Questi farmaci determinano numerosi effetti collaterali tra cui anche tossicità tiroidea con conseguente ipotiroidismo preceduto, talvolta, da tireotossicosi transitoria. Lo scopo di questa rassegna è quello di esaminare sinteticamente il quadro clinico, le metodologie diagnostiche e la rilevanza oncologica delle disfunzioni tiroidee indotte dai TKI. Saranno anche discusse le ipotesi relative ai meccanismi d’azione coinvolti e al potenziale rapporto tra tossicità tiroidea e risposta terapeutica al tumore.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Bibliografia

  1. Hartmann JT, Haap M, Kopp HG, Lipp HP (2009) Tyrosine kinase inhibitors—a review on pharmacology, metabolism and side effects. Curr Drug Metab 10:470–481

    Article  CAS  PubMed  Google Scholar 

  2. Makita N, Liri T (2013) Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis. Thyroid 23:151–159

    Article  CAS  PubMed  Google Scholar 

  3. Desai J, Yassa L, Marqusee E et al. (2006) Hypothyroidism after Sunitinib treatment for patients with Gastrointestinal Stromal Tumors. Ann Intern Med 145:660–664

    Article  PubMed  Google Scholar 

  4. Rini BI, Tamaskar I, Shaheen P et al. (2007) Hypothyroidism in patients with metastatic renal cell carcinoma treated with Sunitinib. J Natl Cancer Inst 99:81–83

    Article  CAS  PubMed  Google Scholar 

  5. Mannavola D, Coco P, Vannucchi G et al. (2007) A novel tyrosine-kinase selective inhibitor, Sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 92:3531–3534

    Article  CAS  PubMed  Google Scholar 

  6. Pani F, Atzori F, Baghino G et al. (2015) Thyroid dysfunction in patients with metastatic carcinoma treated with Sunitinib: is thyroid autoimmunity involved? Thyroid 11:1255–1261

    Article  Google Scholar 

  7. Jonklaas J, Bianco AC, Bauer AJ et al. (2014) Guidelines for the treatment of hypothyroidism. Thyroid 24:1670–1751

    Article  PubMed  PubMed Central  Google Scholar 

  8. Wong E, Rosen LS, Mulay M et al. (2007) Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 17:351–355

    Article  CAS  PubMed  Google Scholar 

  9. Rogiers A, Wolter P, Op de Beeck K et al. (2010) Shrinkage of thyroid volume in sunitinib-treated patients with renal cell carcinoma: a potential marker of irreversible thyroid dysfunction? Thyroid 20:317–322

    Article  CAS  PubMed  Google Scholar 

  10. Kappers MH, van Esch JH, Smedts FM et al. (2011) Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression. J Clin Endocrinol Metab 96:3087–3094

    Article  CAS  PubMed  Google Scholar 

  11. Grossmann M, Premaratne E, Desai J, Davis ID (2008) Thyrotoxicosis during Sunitinib-treatment for renal cell carcinoma. Clin Endocrinol (Oxf) 69:1147–1149

    Article  Google Scholar 

  12. Braun D, Kim TD, Le Coutre P et al. (2012) Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport. J Clin Endocrinol Metab 97:100–105

    Article  Google Scholar 

  13. Brose MS, Nutting CM, Jarzab B et al., DECISION investigators (2014) Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384:319–328

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Alexandrescu DT, Popoveniuc G, Farzanmehr H et al. (2008) Sunitinib-associated lymphocytic thyroiditis without circulating antithyroid antibodies. Thyroid 18:809–812

    Article  PubMed  Google Scholar 

  15. Kust D, Prpić M, Murgić J et al. (2014) Hypothyroidism as a predictive clinical marker of better treatment response to Sunitinib therapy. Anticancer Res 34:3177–3184

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Endocrinologia, Dipartimento di Scienze e Sanità Pubblica, Università degli Studi di Cagliari, Cagliari, Italia

    Fabiana Pani & Stefano Mariotti

Authors
  1. Fabiana Pani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefano Mariotti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fabiana Pani.

Ethics declarations

Conflitti di interesse

Gli autori Fabiana Pani e Stefano Mariotti dichiarano di avere i seguenti conflitti di interesse: Stefano Mariotti: Contributi per partecipazione a Congressi da IBSA Farmaceutici Italia S.r.l. e da Sanofi-Genzyme; contributi per conferenze e partecipazione a gruppi di lavoro da Sanofi_Genzyme. Fabiana Pani: Contributi per partecipazione a Congressi da IBSA Farmaceutici Italia S.r.l. e da Bayer S.p.A.

Consenso informato

Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.

Studi sugli animali

Gli autori di questo articolo non hanno eseguito studi sugli animali.

Additional information

Proposto da Francesco Trimarchi.

Materiale elettronico supplementare

I link al materiale elettronico supplementare sono elencati qui sotto.

(DOC 28 kB)

(DOC 26 kB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pani, F., Mariotti, S. Disfunzioni tiroidee in pazienti con tumori solidi trattati con farmaci inibitori delle tirosino-chinasi. L'Endocrinologo 18, 257–264 (2017). https://doi.org/10.1007/s40619-017-0366-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40619-017-0366-3

Parole chiave

Search

Navigation